Welcome to our dedicated page for Enanta Pharmaceuticals news (Ticker: ENTA), a resource for investors and traders seeking the latest updates and insights on Enanta Pharmaceuticals stock.
Enanta Pharmaceuticals, Inc. develops small-molecule drugs for viral infections and immunological diseases through a chemistry-driven drug discovery approach. News about the company commonly covers its respiratory syncytial virus programs, including zelicapavir, an oral N-protein inhibitor, and EDP-323, an L-protein inhibitor, as well as clinical data presentations at medical and scientific conferences.
Enanta updates also focus on immunology programs targeting drivers of type 2 immune responses, including KIT, STAT6 and MRGPRX2 inhibition. Company releases frequently address candidates such as EDP-978 and EPS-3903, research and development progress, quarterly financial results, management conference participation and royalty revenue tied to its collaboration history.
Enanta Pharmaceuticals (NASDAQ:ENTA) announced plans to report its financial results for the fiscal fourth quarter and year ended September 30, 2020, on November 23, 2020, after market close. A conference call will be held at 4:30 p.m. ET on the same day to discuss the results and provide updates on its business, including research and development efforts in viral infections and liver diseases. Enanta's research is funded by royalties from its collaboration with AbbVie, notably for its hepatitis C drug, Glecaprevir.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company, announced that CEO Jay R. Luly, Ph.D., will participate in a fireside chat at the 4th Annual H.C. Wainwright Virtual NASH Investor Conference on October 5, 2020, at 2:00 pm ET. The event will be accessible via a live webcast on Enanta’s website, with a replay available for 30 days post-presentation.
Enanta focuses on developing small molecule drugs for viral infections and liver diseases, with ongoing research in RSV, NASH, HBV, and COVID-19.